Molecular genetic investigation of hereditary breast and ovarian cancer patients in the Southern Transdanubian region: widening the mutation spectrum and searching for new pathogenic variants using next-generation methods.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
2024
Historique:
received: 30 04 2024
accepted: 19 07 2024
medline: 16 8 2024
pubmed: 16 8 2024
entrez: 16 8 2024
Statut: epublish

Résumé

Hereditary breast and ovarian cancer is a well-known genetic condition, inherited mainly in an autosomal dominant way, which elevates the risk of developing malignancies at a young age in heterozygous carriers. Advances in new generation sequencing have enabled medical professionals to determine whether a patient is harbouring mutations in moderate- or high penetrance susceptibility genes. We conducted a retrospective analysis among 275 patients who underwent genetic counselling and multigene panel testing for hereditary breast and ovarian cancer syndrome in our department. From these patients 74.5% (205/275) were affected by some type of malignancy, while the remaining 25.5% (70/275) had a positive family history of different cancers, suggesting a genetic predisposition. These tests confirmed a genetic variant in 29.8% and 28.6% of these patient groups respectively. The results also mirrored our general knowledge concerning the genetic background of hereditary breast and ovarian cancer, as variants in either one of the

Identifiants

pubmed: 39148954
doi: 10.3389/pore.2024.1611813
pii: 1611813
pmc: PMC11324426
doi:

Substances chimiques

BRCA2 Protein 0
BRCA2 protein, human 0
BRCA1 protein, human 0
BRCA1 Protein 0
Biomarkers, Tumor 0
CDH1 protein, human 0
Antigens, CD 0
Cadherins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1611813

Informations de copyright

Copyright © 2024 Baráti, Maász, Mikó, Bércesi, Kalbani, Bene, Kovács, Mangel and Hadzsiev.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

László Baráti (L)

Department of Medical Genetics, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Anita Maász (A)

Department of Medical Genetics, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Alexandra Mikó (A)

Department of Medical Genetics, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.
Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.

Éva Bércesi (É)

Department of Oncotherapy, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Sultan Al Kalbani (SA)

Department of Medical Genetics, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Judit Bene (J)

Department of Medical Genetics, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Sebestyén Kovács (S)

Urology Clinic, Clinical Centre, University of Pécs, Pécs, Hungary.

László Mangel (L)

Department of Oncotherapy, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Kinga Hadzsiev (K)

Department of Medical Genetics, Clinical Centre, Medical School, University of Pécs, Pécs, Hungary.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH